Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04502472 · ClinicalTrials.gov registry record · Phase 2
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma
A Phase 2 study, sponsored by Inova Health Care Services.
- Terminated
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT04502472: Clinical Trial Phase 2 study, sponsored by Inova Health Care Services.
NCT04502472 is a Phase 2 study that was terminated before completion, run by Inova Health Care Services. The registered enrollment target is 109 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04502472, a Phase 2 study, was terminated before completion, sponsored by Inova Health Care Services.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
The investigators hypothesize that use of convalescent plasma donated from individuals recovered from Coronavirus Disease 2019 (COVID-19) will help expedite recovery of individuals with active, severe COVID-19 infection.
Primary Outcome
Change is clinical status as captured by 7-point ordinal scale to include 1. Death 2. Hospitalized, requiring mechanical ventilation or ECMO 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen--requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen-not requiring ongoing medical care (COVID-19 related or otherwise). 7. No
Interventions
- BIOLOGICAL Convalescent plasma transfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2020-06-06 |
| Est. Completion | 2020-09-30 |
| Phase | Phase 2 |
Why NCT04502472 stopped before completion
NCT04502472 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% lower).
The record links to 0 conditions, and to 1 intervention - of which Convalescent plasma transfusion is the first listed.
NCT04502472 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04502472 about?
NCT04502472 is a clinical study titled "Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma". The investigators hypothesize that use of convalescent plasma donated from individuals recovered from Coronavirus Disease 2019 (COVID-19) will help expedite recovery of individuals with active, severe COVID-19 infection.
What is the current status of trial NCT04502472?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2020-06-06. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT04502472?
The interventions under investigation include: Convalescent plasma transfusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT04502472?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04502472's enrollment target sits among peer trials
109 640th of 2000 higher than 1,361 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI